Free Trial

LAVA Therapeutics (LVTX) Stock Price, News & Analysis

LAVA Therapeutics logo
$1.57 +0.02 (+1.29%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$1.58 +0.00 (+0.32%)
As of 08/29/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About LAVA Therapeutics Stock (NASDAQ:LVTX)

Key Stats

Today's Range
$1.53
$1.58
50-Day Range
$1.31
$1.57
52-Week Range
$0.85
$2.09
Volume
161,708 shs
Average Volume
204,468 shs
Market Capitalization
$41.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.69
Consensus Rating
Hold

Company Overview

LAVA Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
46th Percentile Overall Score

LVTX MarketRank™: 

LAVA Therapeutics scored higher than 46% of companies evaluated by MarketBeat, and ranked 623rd out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    LAVA Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 6 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    LAVA Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about LAVA Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for LAVA Therapeutics are expected to decrease in the coming year, from ($1.13) to ($1.30) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of LAVA Therapeutics is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of LAVA Therapeutics is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    LAVA Therapeutics has a P/B Ratio of 1.48. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.29% of the float of LAVA Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    LAVA Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in LAVA Therapeutics has recently decreased by 28.05%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    LAVA Therapeutics does not currently pay a dividend.

  • Dividend Growth

    LAVA Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.29% of the float of LAVA Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    LAVA Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in LAVA Therapeutics has recently decreased by 28.05%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    LAVA Therapeutics has a news sentiment score of 1.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.12 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for LAVA Therapeutics this week, compared to 0 articles on an average week.
  • MarketBeat Follows

    2 people have added LAVA Therapeutics to their MarketBeat watchlist in the last 30 days.
Receive LVTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LAVA Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

LVTX Stock News Headlines

LAVA Therapeutics N.V. (LVTX) - Yahoo Finance
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.tc pixel
See More Headlines

LVTX Stock Analysis - Frequently Asked Questions

LAVA Therapeutics' stock was trading at $0.9510 at the beginning of the year. Since then, LVTX stock has increased by 65.1% and is now trading at $1.57.

LAVA Therapeutics N.V. (NASDAQ:LVTX) issued its quarterly earnings data on Wednesday, August, 13th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.28) by $0.04.

LAVA Therapeutics (LVTX) raised $100 million in an initial public offering on Thursday, March 25th 2021. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Jefferies and SVB Leerink served as the underwriters for the IPO and Kempen & Co. was co-manager.

LAVA Therapeutics' top institutional shareholders include BML Capital Management LLC (7.49%), Lepercq De Neuflize Asset Management LLC (0.12%) and Rangeley Capital LLC (0.10%).

Shares of LVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that LAVA Therapeutics investors own include Broadcom (AVGO), NVIDIA (NVDA), Adobe (ADBE), Arista Networks (ANET), New Oriental Education & Technology Group (EDU), ServiceNow (NOW) and AppLovin (APP).

Company Calendar

Last Earnings
8/13/2025
Today
9/01/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:LVTX
CIK
1840748
Fax
N/A
Employees
60
Year Founded
N/A

Price Target and Rating

High Price Target
$6.00
Low Price Target
$1.24
Potential Upside/Downside
+71.0%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.05)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$25.11 million
Net Margins
N/A
Pretax Margin
-552.14%
Return on Equity
-106.29%
Return on Assets
-38.24%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
10.78
Quick Ratio
10.78

Sales & Book Value

Annual Sales
$11.98 million
Price / Sales
3.45
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.06 per share
Price / Book
1.48

Miscellaneous

Outstanding Shares
26,310,000
Free Float
23,806,000
Market Cap
$41.31 million
Optionable
Optionable
Beta
0.50
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:LVTX) was last updated on 9/2/2025 by MarketBeat.com Staff
From Our Partners